Appropriate selection of an aggregation inhibitor of fine particles used for inhalation prepared by emulsion solvent diffusion

References

• D'Arcy PF, McElnay JC. The pharmacy and pharmacology of asthma. Halsted Press; 1989.
   Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588–99.
   PubMed Web of Science ®Google Scholar
• Wigley FW, Londono JH, Wood SH, et al. Insulin across respiratory mucosae by aerosol delivery. Diabetes 1971;20:552–6.
   PubMed Web of Science ®Google Scholar
• Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19:3–36.
   Web of Science ®Google Scholar
• Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997;276:1868–71.
   PubMed Web of Science ®Google Scholar
• Ezzati Nazhad Dolatabadi J, Hamishehkar H, Valizadeh H. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol. Drug Dev Ind Pharm 2015;41:1431–7.
   PubMed Web of Science ®Google Scholar
• Pedersen S. Inhalers and nebulizers: which to choose and why. Respir Med 1996;90:69–77.
   PubMed Web of Science ®Google Scholar
• Griffioen RW, de Jongh FH. Inhalation therapy in children younger than 2 years. II. The Practice. Ned Tijdschr Geneeskd 1998;142:1488–93.
   PubMedGoogle Scholar
• Williams RO, III, Brown J, Liu J. Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm Dev Technol 1999;4:167–79.
   PubMed Web of Science ®Google Scholar
• Balducci AG, Cagnani S, Sonvico F, et al. Pure insulin highly respirable powders for inhalation. Eur J Pharm Sci 2014;51:110–17.
   PubMed Web of Science ®Google Scholar
• Newman SP. Inhaler treatment options in COPD. Eur Respir Rev 2005;96:102–8.
   Google Scholar
• Chew NY, Chan HK. The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 2002;15:325–30.
   PubMedGoogle Scholar
• Lobo JM, Schiavone H, Palakodaty S, et al. SCF-engineered powders for delivery of budesonide from passive DPI devices. J Pharm Sci 2005;94:2276–88.
   PubMed Web of Science ®Google Scholar
• Adjei A, Garren J. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm Res 1990;7:565–9.
   PubMed Web of Science ®Google Scholar
• Timsina MP, Martin GP, Marriott C, et al. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 1994;101:1–13.
   Web of Science ®Google Scholar
• Yakubu SI, Assi KH, Chrystyn H. Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen cascade impactor with a mixing inlet: the influence of flow and volume. Int J Pharm 2013;455:213–18.
   PubMed Web of Science ®Google Scholar
• Hajratwala BR. Particle size reduction by a hammer mill I: effect of output screen size, feed particle size, and mill speed. J Pharm Sci 1982;71:188–90.
   PubMed Web of Science ®Google Scholar
• Salazar J, Müller RH, Möschwitzer JP. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets. Eur J Pharm Sci 2013;49:565–77.
   PubMed Web of Science ®Google Scholar
• Ticehurst MD, Basford PA, Dallman CI, et al. Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide. Int J Pharm 2000;193:247–59.
   PubMed Web of Science ®Google Scholar
• Mackin L, Zanon R, Park JM, et al. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry. Int J Pharm 2002;231:227–36.
   PubMed Web of Science ®Google Scholar
• Rasenack N, Müller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res 2002;19:1894–900.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Serigano T, Hino T, et al. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm 1998;172:179–88.
   Web of Science ®Google Scholar
• Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 2004;270:297–306.
   PubMed Web of Science ®Google Scholar
• Zellnitz S, Schroettner H, Urbanetz NA. Influence of surface characteristics of modified glass beads as model carriers in dry powder inhalers (DPIs) on the aerosolization performance. Drug Dev Ind Pharm 2015;41:1710–17.
   PubMed Web of Science ®Google Scholar
• Staniforth JN. Performance-modifying influences in dry powder inhalation systems. Aerosol Sci Technol 1995;22:346–53.
   Web of Science ®Google Scholar
• Zhou QT, Morton DA. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. Adv Drug Deliv Rev 2012;64:275–84.
   PubMed Web of Science ®Google Scholar
• Kaialy W, Nokhodchi A. Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol. Eur J Pharm Sci 2015;68:56–67.
   PubMed Web of Science ®Google Scholar
• Makhlof A, Miyazaki Y, Tozuka Y, Takeuchi H. Cyclodextrins as stabilizers for the preparation of drug nanocrystals by the emulsion solvent diffusion method. Int J Pharm 2008;357:280–5.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Okumura M, Takenaka H. Spherical crystallization: direct spherical agglomeration of salicylic acid crystals during crystallization. Science 1982;216:1127–8.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Niwa T, Handa T, et al. Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method. J Pharm Sci 1989;78:68–72.
   PubMed Web of Science ®Google Scholar
• Maghsoodi M, Hassan-Zadeh D, Barzegar-Jalali M, et al. Improved compaction and packing properties of naproxen agglomerated crystals obtained by spherical crystallization technique. Drug Dev Ind Pharm 2007;33:1216–24.
   PubMed Web of Science ®Google Scholar
• Pandey S, Patil AT. Preparation, evaluation and need of spherical crystallization in case of high speed direct tabletting. Curr Drug Deliv 2014;11:179–90.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 2001;23:39–54.
   Web of Science ®Google Scholar
• Yamamoto H, Kuno Y, Sugimoto S, et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005;102:378–81.
   Web of Science ®Google Scholar
• Tahara K, Miyazaki Y, Kawashima Y, et al. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm 2011;77:84–8.
   PubMed Web of Science ®Google Scholar
• Niwa T, Takeuchi H, Hino T, et al. In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J Pharm Sci 1994;83:727–32.
   PubMed Web of Science ®Google Scholar
• Yang M, Yamamoto H, Kurashima H, et al. Design and evaluation of poly(DL-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation. Eur J Pharm Sci 2012;46:374–80.
   PubMed Web of Science ®Google Scholar
• McIntire GL, Bacon ER, Toner JL, et al. Pulmonary delivery of nanoparticles of insoluble, iodinated CT X-ray contrast agents to lung draining lymph nodes in dogs. J Pharm Sci 1998;87:1466–70.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Omori H, Kinoshita M, et al. A novel analgesic, ONO-2921, causes a use-dependent inhibition of human N-type (.Alpha.1B) Ca2+ channels and increases inactivated state. Jpn J Pharmacol 2002;88:162.
   Google Scholar
• Nishi M, Ishikawa T, Matsumoto Y, et al. Biochemical and physical treatment in rat neuropathic pain and nerve growth factor. Pain Res 2004;19:141–9.
   Google Scholar
• Pham DD, Fattal E, Ghermani N, et al. Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients. Int J Pharm 2013;454:668–77.
   PubMed Web of Science ®Google Scholar
• Eggersdorfer ML, Pratsinis SE. Agglomerates and aggregates of nanoparticles made in the gas phase. Adv Powder Technol 2014;25:71–90.
   Web of Science ®Google Scholar
• Hermans PH, Weidinger A. Quantitative X-ray investigations on the crystallinity of cellulose fibers. A background analysis. J Appl Phys 1948;19:491–506.
   Web of Science ®Google Scholar
• Meenach SA, Anderson KW, Zach HJ, et al. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci 2013;49:699–711.
   PubMed Web of Science ®Google Scholar
• Li X, Vogt FG, Hayes D, Jr., Mansour HM. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. Eur J Pharm Sci 2014;52:191–205.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Yamamoto H, Takeuchi H, et al. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Pharm Biopharm 1998;45:41–8.
   PubMed Web of Science ®Google Scholar
• ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). Impurities: Guideline for Residual Solvents Q3C (R3), 1997.
   Google Scholar
• Oster CG, Wittmar M, Bakowsky U, Kissel T. DNA nano-carriers from biodegradable cationic branched polyesters are formed by a modified solvent displacement method. J Control Release 2006;111:371–81.
   PubMed Web of Science ®Google Scholar
• Youm I, Bazzil JD, Otto JW, et al. Influence of surface chemistry on cytotoxicity and cellular uptake of nanocapsules in breast cancer and phagocytic cells. AAPS J 2014;16:550–67.
   PubMed Web of Science ®Google Scholar
• Shi C, Ahmad KS, Wang K, Schneider M. Improved delivery of the natural anticancer drug tetrandrine. Int J Pharm 2015;479:41–51.
   PubMed Web of Science ®Google Scholar
• Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm 2002;238:77–92.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 2006;58:1688–713.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 2006;23:931–40.
   PubMed Web of Science ®Google Scholar
• Kasten G, Silva LF, Lemos-Senna E. Development of low density azithromycin-loaded polycaprolactone microparticles for pulmonary delivery. Drug Dev Ind Pharm 2015;12:1–12.
   Google Scholar
• Kawashima Y, Serigano T, Hino T, et al. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm Res 1998;15:1748–52.
   PubMed Web of Science ®Google Scholar
• Karner S, Urbanets NA. The impact of electrostatic charge in pharmaceutical powders with specific focus on inhalation-powders. J Aerosol Sci 2011;42:428–45.
   Web of Science ®Google Scholar
• Kim YH, Sioutas C, Shing KS. Influence of stabilizers on the physicochemical characteristics of inhaled insulin powders produced by supercritical antisolvent process. Pharm Res 2009;26:61–71.
   PubMed Web of Science ®Google Scholar
• Yang M, Cui F, You B, et al. A novel pH-dependent gradient-release delivery system for nitrendipine: I. Manufacturing, evaluation in vitro and bioavailability in healthy dogs. J Control Release 2004;98:219–29.
   PubMed Web of Science ®Google Scholar
• Pandya N, Pandya M, Bhaskar VH. Preparation and in vitro characterization of porous carrier-based Glipizide floating microspheres for gastric delivery. J Young Pharm 2011;3:97–104.
   PubMedGoogle Scholar